<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01172132</url>
  </required_header>
  <id_info>
    <org_study_id>AOM 08235</org_study_id>
    <nct_id>NCT01172132</nct_id>
  </id_info>
  <brief_title>The Use of Intensive Care in Critically Ill Cancer Haematological Patients: &quot;TRIAL-OH&quot;</brief_title>
  <official_title>Long Term Outcomes in Critically Ill Haematological Patients. The Use of Intensive Care in Critically Ill Cancer Haematological Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine:

        -  Condition of intensive care unit (ICU) admission in patients with haematological
           malignancies.

        -  ICU hospital and up to one year mortality.

        -  Assessment of post ICU burden and health related quality at 90-d and 1 year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To identify prognostic factors of short and medium term mortality, by underlining the
           respective weights of organ dysfunction and characteristics of underlined malignancy

        2. Evaluate the health related quality of life of intensive care survivors(SF36)

        3. Impact of intensive care on families burden (HADS, IES).

        4. Assess clinicians' satisfaction ( intensivists, haematologists and intensive care
           nurses) in relation to medical decision-making.

        5. Establish the relevance of antifungal treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival status at one year</measure>
    <time_frame>1 year</time_frame>
    <description>survival status (alive or death) at one year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life of patients and their relatives</measure>
    <time_frame>day 90 and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>1 week (estimated mean time until ICU discharge)</time_frame>
    <description>survival status at ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival status</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>3 weeks (estimated mean time until Hospital discharge)</time_frame>
    <description>survival status at hospital discharge</description>
  </secondary_outcome>
  <enrollment type="Actual">1011</enrollment>
  <condition>Hematological Malignancies</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with heamatological malignancy adressed to ICU
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hematological malignancies

          -  hospitalization in ICU

          -  age &gt;= 18 years

        Exclusion Criteria:

          -  Patients who have already participated to TRIAL-OH
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elie Azoulay, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint-Louis Hospital, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Saint-Louis, AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Camous L, Lemiale V, Canet E, Max A, Schnell D, Le Goff J, Rabbat A, Schlemmer B, Azoulay E. Clinical features of H1N1 2009 infection in critically ill immunocompromised patients. Crit Care. 2010;14(2):139. doi: 10.1186/cc8927. Epub 2010 Apr 14.</citation>
    <PMID>20392286</PMID>
  </reference>
  <results_reference>
    <citation>Lemiale V, Resche-Rigon M, Mokart D, Pène F, Rabbat A, Kouatchet A, Vincent F, Bruneel F, Nyunga M, Lebert C, Perez P, Meert AP, Benoit D, Chevret S, Azoulay E. Acute respiratory failure in patients with hematological malignancies: outcomes according to initial ventilation strategy. A groupe de recherche respiratoire en réanimation onco-hématologique (Grrr-OH) study. Ann Intensive Care. 2015 Dec;5(1):28. doi: 10.1186/s13613-015-0070-z. Epub 2015 Sep 30.</citation>
    <PMID>26429355</PMID>
  </results_reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2010</study_first_submitted>
  <study_first_submitted_qc>July 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2010</study_first_posted>
  <last_update_submitted>April 15, 2016</last_update_submitted>
  <last_update_submitted_qc>April 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Bone-Marrow Transplant</keyword>
  <keyword>Neutropenia</keyword>
  <keyword>Acute respiratory failure</keyword>
  <keyword>Mechanical ventilation</keyword>
  <keyword>Post ICU burden</keyword>
  <keyword>ICU triage</keyword>
  <keyword>Dialysis</keyword>
  <keyword>Septic shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

